ArticleBMC cancer2026
High VRK2 expression level predicts unfavorable survival outcomes in nasopharyngeal carcinoma.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundEpstein–Barr virus (EBV)–associated nasopharyngeal carcinoma (NPC) is an endemic epithelial malignancy in East and Southeast Asia, yet reliable molecular markers for risk stratification remain limited. Vaccinia-related kinase 2 (VRK2), a serine/threonine kinase implicated in cell proliferation, stress responses, and inflammatory signaling, has not been comprehensively evaluated in NPC.
methodsIn this retrospective study, we assessed the prognostic impact of VRK2 expression in 124 patients with histologically confirmed NPC. VRK2 protein levels were determined by immunohistochemical staining and correlated with clinicopathological parameters and survival outcomes.
resultsHigh VRK2 expression was significantly associated with advanced pathological stage (p = 0.006). Patients with high VRK2 levels had markedly poorer disease-specific survival (DSS), distant metastasis-free survival (DMeFS), and local recurrence-free survival (LRFS) on univariate analysis (all p < 0.001). In multivariate Cox regression models, elevated VRK2 expression remained an independent predictor of adverse outcomes, with hazard ratios of 2.904 (95% CI: 1.678–5.026) for DSS, 3.566 (95% CI: 1.874–6.784) for DMeFS, and 2.885 (95% CI: 1.411–5.898) for LRFS (all p < 0.001).
conclusionsThese findings suggest that VRK2 may actively contribute to the aggressive phenotype and enhanced progression of Epstein–Barr virus (EBV)-associated NPC by modulating cellular signaling pathways. The overexpression of VRK2 may reflect underlying molecular alterations associated with metastasis and treatment resistance. Therefore, VRK2 expression may serve not only as a clinically relevant prognostic biomarker but also as a potential molecular target to improve patient stratification and guide individualized therapeutic interventions in NPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.